Best VIP Dosage for Inflammation — Research Protocol Guide

Research published in the Journal of Neuroimmunology found that vasoactive intestinal peptide (VIP) administered at 100 mcg intranasally reduced circulating TNF-α levels by 40% in acute inflammation models. But only when administered every 8–12 hours during the inflammatory window. Single daily dosing showed minimal effect. The anti-inflammatory mechanism runs through cAMP elevation in macrophages and dendritic cells, which suppresses NF-κB translocation and downstream cytokine production. But the half-life of VIP in circulation is approximately 90 seconds, meaning sustained effect requires either continuous infusion or repeated dosing at intervals shorter than most peptide protocols use.

Our team has reviewed peptide stability data across hundreds of research protocols in this space. The pattern is consistent every time: dosing frequency matters as much as total daily dose when working with peptides that clear this rapidly.

What is the best VIP dosage for inflammation in research settings?

The best VIP dosage for inflammation ranges from 100 mcg to 300 mcg daily, with dosing frequency and administration route (intranasal vs subcutaneous) determining bioavailability and anti-inflammatory efficacy. Intranasal delivery achieves 10–15% systemic absorption; subcutaneous administration reaches near-complete uptake. Research protocols typically use 100 mcg intranasal every 8 hours or 50–100 mcg subcutaneous twice daily to maintain therapeutic plasma concentrations throughout the inflammatory cycle.

Yes, VIP shows dose-dependent anti-inflammatory effects. But the mechanism isn't as straightforward as 'more peptide equals more suppression.' VIP binds to VPAC1 and VPAC2 receptors expressed on immune cells, triggering intracellular cAMP signalling that shifts macrophage polarisation from M1 (pro-inflammatory) to M2 (regulatory). Dosing above 300 mcg daily in research models hasn't shown proportional benefit and may trigger receptor desensitisation. This article covers exact dosing protocols used in published studies, how administration route changes effective concentration, and what preparation errors negate anti-inflammatory activity entirely.

VIP's Anti-Inflammatory Mechanism and Dosing Rationale

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide that functions as both a neurotransmitter and an immunomodulator. Its anti-inflammatory action centres on two G-protein-coupled receptors. VPAC1 and VPAC2. Expressed on macrophages, dendritic cells, T cells, and intestinal epithelial cells. Receptor binding elevates intracellular cyclic AMP (cAMP), which activates protein kinase A (PKA) and inhibits nuclear factor kappa B (NF-κB) translocation to the nucleus. NF-κB is the master regulator of pro-inflammatory cytokine transcription. Blocking its nuclear entry suppresses TNF-α, IL-6, IL-12, and IL-1β production at the transcriptional level.

The rationale for 100–300 mcg daily dosing comes from rodent and primate studies where this range consistently demonstrated measurable cytokine suppression without adverse effects. A 2018 study in Molecular Therapy used 200 mcg intranasal VIP daily in rhesus macaques with experimental autoimmune encephalomyelitis and documented 60% reduction in cerebrospinal fluid IL-17 levels compared to vehicle controls. The dose-response curve plateaus above 300 mcg. Higher doses don't produce proportionally greater suppression, suggesting receptor saturation.

Administration route profoundly affects effective dose. Intranasal VIP bypasses first-pass hepatic metabolism and delivers peptide directly to the CNS via olfactory and trigeminal nerve pathways. But systemic bioavailability is only 10–15%. Subcutaneous injection achieves near-complete absorption but distributes systemically rather than concentrating in neural tissue. For systemic inflammation (e.g., colitis models, sepsis), subcutaneous is preferable; for neuroinflammation (e.g., MS models, traumatic brain injury), intranasal targets the site more effectively.

Here's what our experience shows: researchers unfamiliar with VIP often dose once daily at 200–300 mcg and see inconsistent results. VIP's plasma half-life is approximately 90 seconds. It's cleared by enzymatic degradation (dipeptidyl peptidase IV, neutral endopeptidase) faster than almost any other research peptide. Effective protocols split the daily dose into 2–3 administrations to maintain therapeutic levels.

Published Dosing Protocols Across Inflammation Models

Clinical and preclinical literature on VIP anti-inflammatory dosing spans autoimmune disease, acute injury models, and chronic inflammatory states. The most-cited dosing protocols come from inflammatory bowel disease (IBD) research, where VIP's receptor expression in gut-associated lymphoid tissue makes it a logical target.

A Phase II trial published in Gut in 2012 tested intranasal VIP in ulcerative colitis patients at 200 mcg three times daily for 8 weeks. Primary endpoint was clinical remission (defined as Mayo score ≤2 with no subscore >1). Results: 37% remission rate vs 19% placebo, with treatment effect most pronounced in patients with left-sided disease. Endoscopic healing occurred in 42% of VIP-treated patients. Adverse events were minimal. Transient nasal irritation in 18%, no serious AEs attributed to VIP.

Rheumatoid arthritis models used different dosing. A 2015 Arthritis Research & Therapy study administered 100 mcg VIP subcutaneously twice daily in collagen-induced arthritis (CIA) mice. Paw swelling was reduced by 55% compared to saline-treated controls, and histological analysis showed significantly lower synovial inflammation scores. Serum IL-6 and TNF-α were reduced by 48% and 62%, respectively. The researchers tested 50 mcg, 100 mcg, and 200 mcg twice-daily doses. The 100 mcg dose produced maximal benefit with no additional effect at 200 mcg.

Neuroinflammation protocols skew higher. A 2020 Brain, Behavior, and Immunity paper used 300 mcg intranasal VIP daily (divided into morning and evening doses) in a traumatic brain injury model. Microglial activation markers (Iba1, CD68) were reduced by 40–50% in injured cortex compared to vehicle-treated animals. Interestingly, single daily dosing at 300 mcg was less effective than split dosing at 150 mcg twice daily. Reinforcing the importance of maintaining plasma levels given VIP's rapid clearance.

Real Peptides supplies research-grade VIP in lyophilised form with exact amino-acid sequencing verified by mass spectrometry. Purity and consistency matter when replicating published protocols. Degraded or impure peptide won't produce reproducible anti-inflammatory effects regardless of dose.

Route-Specific Bioavailability and Effective Dosing

Administration route determines not just how much VIP reaches circulation, but where it concentrates. Intranasal delivery achieves direct nose-to-brain transport via olfactory and trigeminal pathways, bypassing the blood-brain barrier. A critical advantage for neuroinflammatory applications. Subcutaneous injection distributes systemically but doesn't preferentially target neural tissue.

Intranasal bioavailability is approximately 10–15% based on pharmacokinetic studies in primates. This means a 200 mcg intranasal dose delivers roughly 20–30 mcg systemically. The remaining peptide either degrades in nasal mucosa or undergoes local absorption without entering systemic circulation. For neuroinflammation research, this 'inefficiency' is actually beneficial. The peptide reaches CNS tissue at higher local concentrations than systemic dosing would achieve.

Subcutaneous injection achieves near-complete absorption (85–95% bioavailability) but lacks CNS targeting. A 100 mcg subcutaneous dose delivers approximately 85–95 mcg systemically, making it 6–8 times more systemically bioavailable than the same dose given intranasally. For peripheral inflammation (IBD, arthritis, sepsis models), subcutaneous is the more efficient route. For MS, Parkinson's disease, or TBI models, intranasal is standard despite lower systemic uptake.

Intravenous VIP has been tested in sepsis models at much lower doses. 25–50 mcg bolus followed by continuous infusion at 10 mcg/hour. The short half-life makes IV bolus dosing impractical outside of acute care settings. Continuous infusion maintains steady-state levels but isn't feasible for outpatient or chronic-use protocols.

Oral VIP is essentially non-viable. Peptide bonds are cleaved by gastric acid and pancreatic proteases before absorption can occur. Encapsulation strategies and enteric coatings have been tested but haven't achieved reproducible bioavailability.

Here's the honest answer: route selection should be dictated by the inflammation site, not convenience. Researchers sometimes default to subcutaneous because it's familiar, but intranasal is superior for CNS targets despite requiring higher nominal doses to achieve equivalent systemic exposure. The 'best' VIP dosage for inflammation depends entirely on whether you're targeting brain, gut, joints, or systemic cytokine levels.

VIP Dosage for Inflammation: Research vs Clinical Comparison

What If: VIP Dosage for Inflammation Scenarios

What If I'm Replicating a Published Protocol but Seeing No Anti-Inflammatory Effect?

Verify peptide purity and storage first. VIP degrades rapidly at room temperature and loses activity if exposed to repeated freeze-thaw cycles. Store lyophilised VIP at −20°C; once reconstituted with sterile water or bacteriostatic saline, refrigerate at 2–8°C and use within 7 days. Reconstituted VIP left at room temperature for more than 2 hours loses measurable bioactivity. If storage is correct, confirm dosing frequency matches the published protocol exactly. Single daily dosing at 200 mcg won't replicate results from studies using 100 mcg twice daily because plasma levels never reach therapeutic range.

What If the Research Model Requires Both Systemic and CNS Anti-Inflammatory Effects?

Combine routes. Administer 100 mcg subcutaneously in the morning for systemic cytokine suppression and 150 mcg intranasally in the evening for CNS targeting. This dual-route approach has been used in experimental autoimmune encephalomyelitis (EAE) models where both peripheral immune activation and CNS inflammation drive pathology. Total daily VIP remains within the 250–300 mcg range but achieves broader tissue distribution than either route alone.

What If Intranasal Administration Causes Nasal Irritation or Poor Absorption?

Switch to a buffered reconstitution vehicle. PH 7.2–7.4 phosphate-buffered saline reduces mucosal irritation compared to unbuffered sterile water. Administer smaller volumes per nostril (50 mcg in 0.1 mL per side rather than 100 mcg in 0.2 mL single-nostril) to improve retention and reduce runoff. If irritation persists, subcutaneous becomes the fallback despite losing CNS-specific targeting. Systemic anti-inflammatory effects remain intact.

The Unvarnished Truth About VIP Anti-Inflammatory Dosing

Let's be direct: VIP isn't going to replace corticosteroids or TNF inhibitors in clinical practice anytime soon. The peptide's 90-second half-life and intranasal/subcutaneous delivery requirements make it impractical for most therapeutic applications outside of research settings. The published trials show statistically significant cytokine suppression, but the effect sizes are modest compared to biologics. A 40% reduction in TNF-α sounds impressive until you compare it to the 80–90% suppression achieved by adalimumab. VIP's real value lies in research models where you need targeted, receptor-specific anti-inflammatory signalling without the systemic immunosuppression that comes with steroids or broad-spectrum biologics. It's a precision tool, not a sledgehammer. And the dosing protocols reflect that.

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide with well-documented anti-inflammatory properties mediated through VPAC1 and VPAC2 receptor signalling on immune cells. The best VIP dosage for inflammation in research settings ranges from 100 to 300 mcg daily, with administration route and dosing frequency determining bioavailability and tissue-specific targeting. Intranasal delivery achieves CNS penetration with 10–15% systemic absorption; subcutaneous injection provides near-complete systemic uptake without CNS preference. Published protocols in inflammatory bowel disease, rheumatoid arthritis, and neuroinflammation models consistently use split dosing (2–3 times daily) to compensate for VIP's approximately 90-second plasma half-life. Single daily dosing produces inconsistent results regardless of total dose.

Phase II clinical trial data in ulcerative colitis demonstrated 37% remission with 200 mcg intranasal VIP three times daily versus 19% placebo, with endoscopic healing in 42% of treated patients. Rodent arthritis models showed maximal benefit at 100 mcg subcutaneous twice daily, with no additional effect at higher doses. Suggesting receptor saturation limits dose-response beyond 300 mcg daily. Storage matters as much as dose: lyophilised VIP must be kept at −20°C before reconstitution and refrigerated at 2–8°C once mixed, with use within 7 days to prevent activity loss.

The information in this article is for research and educational purposes. Dose selection, administration protocols, and experimental design decisions should align with institutional review board (IRB) or institutional animal care and use committee (IACUC) guidelines and relevant published methodologies. Real Peptides provides research-grade peptides synthesised through small-batch production with exact amino-acid sequencing verified by mass spectrometry. Purity and consistency are non-negotiable when replicating published anti-inflammatory protocols. Explore our full peptide collection to find research compounds suited to your specific experimental needs.

If VIP's ultra-short half-life complicates your dosing protocol, raise the question before committing to a multi-week study. Switching to a longer-acting analogue or adjusting frequency mid-protocol invalidates baseline comparisons and wastes both peptide and time.